Biologic Drugs With Established Pharmaceutical Class: Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
Biologic Drugs With Established Pharmaceutical Class: Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | BEYFORTUS | nirsevimab-alip | Injection | 761328 | 2023-07-17 | ⤷ Start Trial | ⤷ Start Trial |
| Merck Sharp & Dohme Llc | ENFLONSIA | clesrovimab-cfor | Injection | 761432 | 2025-06-09 | ⤷ Start Trial | ⤷ Start Trial |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Patent Expiration |
